Physician profile
Jack Barfield Freeman
NPI 1295704831
$6,221.06
in general payments reported to CMS, 2019-2025
46 companies · $839 in 2025
The $839 reported for 2025 was more than what 90% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $825 · 2021: $678 · 2022: $937 · 2023: $674 · 2024: $734 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.63 | 2019-2023 | |
| Astellas Pharma US INC | $568.82 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $541.38 | 2019-2024 | Wegovy |
| Amgen INC. | $493.65 | 2019-2023 | Prolia, Evenity |
| Therapeuticsmd, INC. | $385.30 | 2019-2022 | |
| Hologic Sales and Service, LLC | $357.29 | 2019-2025 | Acessa Provu System, Aptima, Novasure |
| Pfizer INC. | $333.51 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.66 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $301.25 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $239.17 | 2022-2025 | Jada System, Nexplanon |
| Mayne Pharma Commercial LLC | $215.06 | 2022-2025 | |
| Scynexis, INC. | $174.48 | 2022 | |
| Myovant Sciences INC. | $148.26 | 2021-2022 | |
| Lupin INC. | $141.08 | 2019-2020 | |
| Shield Therapeutics INC | $136.84 | 2023-2024 | Accrufer |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.